The European healthcare technology landscape entering the second half of the 2026 fiscal year is characterised by an unprecedented transition from the speculative fragmentation of the early 2020s to a disciplined era of industrial maturity.At the center of this metamorphosis is the French Prise en Charge Anticipée Numérique (PECAN) framework, which has now completed its initial three year implementation cycle since its inception in early 2023.

The European healthcare technology IPO landscape is entering a phase of "Rational Exuberance" in 2026, following a prolonged drought stretching from late 2021 through 2025. The IPO window is reopening—early February 2026 saw biotech companies pull in more than $1 billion from public markets in a single week, including Belgium's Agomab Therapeutics scoring a $200 million NASDAQ listing. However, the European HealthTech IPO market remains highly selective, accessible primarily

The global Electronic Health Record (EHR) market is currently undergoing a transformative period of "Industrial Maturity," characterised by a significant realignment of capital among strategic owners and a tactical shift in private equity investment. This "Great Rationalisation" is being driven by a convergence of high-intensity capital requirements for artificial intelligence infrastructure, shifting domestic reimbursement landscapes, and a "Regulatory Darwinism" that has s

The European HealthTech and MedTech M&A landscape in 2026 is poised for significant strategic acceleration, marking a transition from cautious, volume-driven dealmaking to high-value, transformative transactions. Deal flow is consolidating toward fewer but substantially larger deals, with market participants prioritising scalable technologies with robust clinical validation and AI integration capabilities.